INTERVIEW : USA - ANTITRUST - SECTEUR PHARMACEUTIQUE

Marc Brotman (Pfizer) : U.S. and global antitrust issues from a pharmaceutical in-house counsel perspective

Interview réalisée par Kent Bernard, Fordham School of Law and Anna Pavlik, Institute of Competition Law.

What is your background ? I’ve had a focus on antitrust work since starting at Weil Gotshal, with my first large matter being the predatory pricing case that Northwest and Continental Airlines brought against our client American Airlines. I also worked on a trade secret case for Quaker Oats during my tenure there and a number of merger analyses and reviews by the FTC and DOJ. Since coming to Pfizer, in addition to my antitrust work, I’ve provided legal counsel on some of Pfizer’s largest and highest profile medicines and currently support Pfizer’s Corporate Affairs division. While my pre-Pfizer experience was U.S. focused, my work here has required me to counsel on a global basis and interact with regulators across numerous jurisdictions. Over your fourteen years of career at Pfizer,

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Pfizer (New York)
  • Fordham University
  • United First Partners (New York)

Citation

Marc Brotman, Kent Bernard, Anna M. Pavlik, Marc Brotman (Pfizer) : U.S. and global antitrust issues from a pharmaceutical in-house counsel perspective, février 2014, Concurrences N° 1-2014, Art. N° 62204, pp. 7-9

Visites 715

Toutes les revues